76801-94-0

Basic information

• Product Name: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate
• Synonyms: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate;5-Amino-N,Na€-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide Tetraacetate
• CAS NO: 76801-94-0
• Molecular Formula: C₂₂H₂₆I₃N₃O₁₀
• Molecular Weight: 873.16935
• Product Categories: Aromatics, Isotope Labelled Compounds, Labeling and Diagnostics Reagents
• Mol File: 76801-94-0.mol

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Dichloromethane
• CAS DataBase Reference: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(76801-94-0)
• EPA Substance Registry System: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(76801-94-0)

Safety Data

• Hazardous Substances Data: 76801-94-0(Hazardous Substances Data)

Usage

Uses

Used in Medical Imaging Industry:
5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide Tetraacetate is used as an intermediate in the production of X-ray contrast agents for enhancing the visibility of internal structures during medical imaging procedures. It contributes to the development of contrast agents such as Iohexol, Ioversol, Ioxilan, and Iopamidol, which are essential for diagnostic imaging in various medical applications.

Upstream product

• 76801-93-9 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide 
• 108-24-7 acetic anhydride 
• 99-31-0 5-aminoisophthalic acid 
• 111453-32-8 5-amino-N-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamic acid 
• 37441-29-5 5-amino-2,4,6-triiodoisophthalic acid dichloride 
• 35453-19-1 2,4,6-triiodo-5-aminoisophthalic acid 

Downstream Products

• 136453-21-9 N,N'-Bis<2,3-bis(acetyloxy)propyl>-2,4,6-triiodo-5-<<(2-propenyloxy)acetyl>amino>-1,3-benzenedicarboxamide 
• 182758-12-9 Acetic acid 1-acetoxymethyl-2-[3-(4-chloro-butyrylamino)-5-(2,3-diacetoxy-propylcarbamoyl)-2,4,6-triiodo-benzoylamino]-ethyl ester 
• 178814-53-4 N-[3-acetoxymethyl-5-(2,3-diacetoxypropylaminocarbonyl)-2,4,6-triiodophenyl]-N'[3,5-bis(2,3-diacetoxypropylaminocarbonyl)-2,4,6-triiodophenyl]urea 
• 126736-37-6 5-methoxyacetylamino-N,N'-bis(2,3-diacetoxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 87785-51-1 5-(acetoxyacetylamino)-N,N'-bis(2,3-diacetoxypropyl)-2,4,6-triiodoisophthalamide 
• 78649-41-9 iomeprol 
• 136453-24-2 N,N'-Bis[2,3-bis(Acetyloxy)propyl]-5-[(5-chloro-1-oxo-pentyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-19-5 N,N'-bis-[2,3-bis-(acetyloxy)-1-propyl]-5-[4-chloro-1-oxobutyl]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-08-2 N,N'-Bis-[2,3-diacetyloxypropyl]-5-[3-bromo-2-oxo-1-pyrrolidinyl]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 182758-15-2 N,N'-Bis[2,3-bis(acetyloxy)-1-propyl]-5-[(2,6-dibromo-1-oxo-hexyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 153714-15-9 N,N'-Bis[2,3-bis(acetyloxy)propyl]-2,4,6-tri-iodo-5-[[(tetrahydro-2-furanyl)carbonyl]-amino]-1,3-benzenedicarboxamide 
• 136453-01-5 N,N'-bis<2,3-bis(acetyloxy)propyl>-5-<4-(hydroxymethyl)-2-oxo-3-oxazolidinyl>-2,4,6-triiodo-1,3-benzenedicarboxamide 

Relevant articles and documents

NOVEL INTERMEDIATE COMPOUND AND PREPARATION PROCESS OF IOMEPROL USING THEREOF

The present invention relates to a novel intermediate compound of iomeprol, a production method thereof, and a method for producing iomeprol using the same. More specifically, the present invention relates to a method for producing iomeprol used as X-ray vascular contrast agents in an economically feasible way with high purity using a novel intermediate N,Nandprime;-bis(2,3-diacetylatepropyl)-5-(2-acetoxy-N-methylacetoamide)-2,4,6-triiodoisophthalamide. The present invention further relates to a purification method thereof.COPYRIGHT KIPO 2017

Contrast agents

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a benze

CONTRAST AGENTS AND DIAGNOSTIC COMPOSITIONS BASED ON IODINE-CONTAINING CYANURIC ACID DERIVATIVES

The present invention relates to a class of compounds of Formula (I) and to diagno stic compositions containing such compounds where the compounds are iodine conta ining compounds. More specifically the iodine containing compounds are chemical compounds containing a cyanuric acid scaffolding moiety allowing for the arrange ment of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imag ing and in particular in X-ray imaging and to contrast media containing such com pounds .

Urea-linked, iodinated bis phenyl compounds for X-ray contrast media

The invention provides iodinated bis phenyl compounds, useful as X-ray contrast agents, of formula I STR1 (wherein each C6 R5 moeity may be the same or different; each R denotes a hydrogen or iodine atom or a group M, two or three non-adjacent R groups on each C6 R5 moiety denoting iodine atoms and one, two or three R groups on each C6 R5 moiety denoting M groups; X denotes a group providing a 1, 2 or 3 atom chain linking the two C6 R5 groups, preferably where X is or contains in the bridging chain a carbonyloxy group each C6 R5 group being a triodophenyl group or a group in which each R is other than hydrogen; and each M is independently a non-ionic hydrophilic moiety, M preferably being a non-ionic hydrophilic moiety comprising a monohydroxy- or polyhydroxy-alkyl group) and isomers, especially stereoisomers and rotamers, thereof.

Starch microspheres as carriers for X-ray imaging contrast agents: Synthesis and stability of new amino-acid linker derivatives

The relative stability of particulate contrast agents for X-ray imaging, consisting of a succinic-acid derivative of a water-soluble X-ray contrast agent bound to starch particles through an amino-acid ester bond, has been studied. To investigate the effect of chain length of the amino-acid linker on degradation rate, two glycine-linked derivatives and a corresponding β-alanine-linked derivative were prepared as model compounds. The cleavage rate of the amino-acid ester bond in the starch particle β-alanine derivative had a significantly lower cleavage rate than in the corresponding glycine derivatives; after 22 h in human blood serum at 37°C the remaining fraction of the undegraded β-alanine-linked derivative was 78%, while 31.1 and 29.3% were the remaining fractions of the two glycine-linked derivatives. The cleavage data correlated well with biphasic cleavage processes with two distinct half lives for the respective pseudo first order processes. The second preparation with the glycine linker had a cleavage profile and rate equivalent to that of the first one in human blood serum, but the corresponding hydrolysis in phosphate buffer was significantly slower with 79.9%-remaining fraction after 22 h, and was apparently a monophasic pseudo first order reaction. Variation of the degradability of the starch matrix had apparently no significant effect on the cleavage rates of the linker. This suggests that components in the human blood serum catalyze the cleavage of the ester bond in these derivatives and that a fraction of the covalently bound contrast agent had a significantly slower cleavage rate from the matrix. The derivative with a glycine linker between the carrier matrix and the contrast agent is a promising candidate for liver and spleen directed X-ray contrast with respect to density of contrast generating iodine and biodegradability.

Nonionic radiographic contrast agents

Novel nonionic contrast agents of the formula STR1 or dimers of the formula STR2 are disclosed where X, Z and R1 -R5 are as defined herein.

Heterocyclic Nonionic X-ray Contrast Agents. 3. The Synthesis of 5--2,4,6-triiodo-1,3-benzenedicarboxamide Derivatives

The syntheses of 2,4,6-triiodo-1,3-benzenedicarboxamide analogs, 12c, 12e, and 17c, of interest as X-ray diagnostic agents and in which the 5 position is linked to the N atom of a 4-(hydroxymethyl)-oxazolidin-2-one moiety, are described.The heterocycle was built from suitably protected 5-amino-2,4,6-triiodo-1,3-benzenedicarboxylic acid derivatives by a three-step procedure consisting of (1) phosgene treatment to obtain the corresponding isocyanates, (2) phenylmercuric chloride-catalyzed addition of glycidol (10) resulting in glycidil carbamates, and (3) pyridine-catalyzed intramolecular N-alkylation, followed by deprotection, to obtain the oxazolidin-2-ones.The intramolecular N-alkylation reaction was highly regioselective and was not appreciably accompanied by O-alkylation products under the experimental conditions employed.The two carboxamide nitrogen atoms in the intermediates and end products carry either 2,3-dihydroxypropyl or 1,3-dihydroxypropyl residues.These highly congested benzenoid compounds exhibited interesting NMR spectral features due to atropisomerism arising from hindrance to free rotation about the three single bonds that link the aromatic moiety to the N-containing functionalities.

Dicarboxylic acid-bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) and x-ray contrast media containing them

Dicarboxylic acid bis-(3,5-dicarbomoyl-2,4,6-triiodoanilides) of general formula I STR1 wherein the amide radicals --CONR1 R2 and --CONR3 R4 are different from one another and R1 is a hydrogen, a lower alkyl radical or R2, R2 is a straight-chain or branched-chain monohydroxy or polyhydroxy alkyl radical, R3 is hydrogen, a lower alkyl radical or R4, R4 is a straight-chain or branched-chain monohydroxy or polyhydroxy alkyl radical, R5 is hydrogen, a lower alkyl radical or a monohydroxy or polyhydroxy alkyl radical, X is a straight-chain or branched-chain alkylene with 1 to 6 carbon atoms, which optionally can be substituted by 1 to 6 hydroxy or alkoxy groups or interrupted by one or more oxygen atoms, possess good pharmacological and physicochemical properties rendering them outstandingly suitable as radiopaque substances in X-ray contrast media for use in all fields of application for X-ray contrast media.

Triiodoisophthalamide X-ray contrast agent

Novel X-ray contrast agents, i.e., N,N'-bis(2,3-dihydroxypropyl)-5-N-(2-hydroxyethyl)glycolamido-2,4,6-triiodoisophthalamide.